APPENDIX 2

ORAL CONTRACEPTION FORMULATIONS USED WITHIN ONE MONTH PRIOR TO ADMISSION, BY NUMBER OF CASE AND CONTROL USERS WHO COULD IDENTIFY SPECIFIC PRODUCT USED

Content of				No. of use	
Estrogen	mg.	Progestogen	mg.	Case	Controls
Sequential products: [1]					
Mestranol	.08	Chlormadinone	2	8	0
Ethinyl estradiol	.1	Dimethisterone	25	5	0
Mestranol	.08	Norethindrone	2	2	0
Combinations: [2]					
Mestranol	.1	do	2	14	9
Do	.1	Norethynodrel	2.5	14	1
Do	.075	do	5	5	2
Do	.1	Ethynodiol acetate	1	4	3
Ethinyl estradiol	.05	Norethindron acetate	2.5	3	4
Mestranol	.05	Norethindrone	1	3	2
Do	.06	do	10	2	1
Do	.15	Norethynodrel	9.85	2	1
Ethinyl estradiol	.05	Medroxyprogesterone acetate	10	1	0

[1] Estrogen administered for 20 or 21 days, estrogen plus progestogen for 5 days.
[2] Administered for 20 or 21 days.

References

1. Ad Hoc Committee for the Evaluation of a Possible Etiologic Relation of Enovid with Thromboembolic Conditions: Final Report on Enovid, Sept. 12, 1962
2. Advisory Committee on Obstetrics and Gynecology, Food and Drug Administration: Report on the Oral Contraceptives, Aug. 1, 1966. U.S. Govt Printing Office, Washington, D.C.
3. Clinical Aspects of Oral Gestogens. Report of a WHO Scientific Group. WHO Tech. Report Series No. 326, Geneva, 1966.
4. Royal College of General Practitioners: Oral Contraception and Thromboembolic Disease. J. Coll Gen Pract, *13:* 267–279, 1967
5. Inman, W. H. W. and Vessey, M. P. Investigation of Deaths from Pulmonary Coronary and Cerebral Thrombosis and Embolism in Women of Child-Bearing Age, Brit Med J, *2:* 193–199, 1968
6. Vessey, M. P. and Doll, R. Investigation of Relation between Use of Oral Contraceptives and Thromboembolic Disease. A Further Report. Brit Med J, *2:* 651–657, 1969
7. Drill, V. A. and Calhoun, D. W. Oral Contraceptives and Thromboembolic Disease. JAMA, *206:* 77–84, 1968
8. Doll, R., Inman, W. H. W. and Vessey, M. P. "Concerning the British Data" (letter to the editor). JAMA, *297:* 1150–1151, 1969
9. Ryder, N. B. and Westoff, C. F., Use of oral contraception in the United States, 1965, SCIENCE, *153:* 1199, 1966
10. Daniel, D. G., Campbell, H. and Turnbull, A. C. Puerperal Thromboembolism and Suppression of Lactation. Lancet, Aug. 5, 1967, p. 287–289
11. Tindall, V. R. Factors Influencing Puerperal Thrombo-embolism J Obstet Gynaec Brit Comm, *75:* 1324–1327, 1968
12. Dugdale, M. and Masi, A. T. Blood clotting effects of the oral contraceptives *IN* Report on the Oral Contraceptives, Advisory Committee on Obstetrics and Gynecology, Food and Drug Administration, 1969 (in press)

B. TRENDS IN MORTALITY FROM THROMBOEMBOLIC DISORDERS

Philip E. Sartwell, M.D. and Charles Anello, Sc. D.

Mortality rates for thromboembolism have been examined for the main purpose of ascertaining whether these rates have changed in a way consistent with an effect of oral contraceptive use. A second purpose of this report is to